ISSN: 2451-0629
Archives of Medical Science - Atherosclerotic Diseases
Current volume Archive About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Official journal of the International Lipid Expert Panel (ILEP)
CALL FOR PAPERS
1/2020
vol. 5
 
Share:
Share:
more
 
 
State of the art paper

Risk of cardiovascular disease with lipoprotein(a) in familial hypercholesterolemia: a review

Jun Watanabe
1
,
Masato Hamasaki
1
,
Kazuhiko Kotani 
1

1.
Division of Community and Family Medicine, Jichi Medical University, Shimotsuke-City, Japan
Arch Med Sci Atheroscler Dis 2020; 5: e148–e152
Online publish date: 2020/07/11
Article file
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

Lipoprotein(a) (Lp[a]) is a low-density lipoprotein (LDL)-like particle that binds to the protein apoprotein(a) (this protein has a structure homologous to plasminogen) [1]. Due to the unique features of Lp(a) (i.e. thrombogenic and atherogenic properties) [2], Lp(a) is recognized as a risk factor of cardiovascular disease (CVD) [36]. Of interest, the blood Lp(a) levels are largely determined by genetic factors [7].

Familial hypercholesterolemia (FH) is an autosomal dominant genetic disease [8]. The main causative genes are related to LDL clearance by the LDL receptor (LDLR), leading to high blood levels of LDL cholesterol (LDL-C) [9]. FH is recognized as a risk factor of CVD [10].

A combinatory relationship between LDL-C and Lp(a) for CVD has been previously suggested, although the previous studies did not specifically examine FH subjects [11, 12]. A few studies also show that FH subjects with high Lp(a) levels had an increased risk of CVD, but these studies were conducted in somewhat specific settings (e.g. in the coronary care unit at a single hospital [13] or during a cascade test screening for family members of FH subjects [14]). As such, the relationship of Lp(a) with CVD outcomes has yet to be characterized in a population limited to FH.

Whether or not the impact of Lp(a) on CVD can be modulated in FH, a condition of high LDL-C levels, is still of interest. In the current study, we therefore conducted a meta-analysis of available studies to determine the relationship of Lp(a) with CVD outcomes in FH subjects.

Material and methods

Candidate articles for this study were searched using PubMed up to April 25, 2020 using the following keywords: “familial hypercholesterolemia” AND (“lipoprotein(a) (Title/Abstract)” AND “cardiovascular disease (Title/Abstract)” AND risk NOT review (Publication type)). Cardiovascular disease was defined as coronary heart disease and stroke (cerebrovascular disease). Studies that focused on the relationship of Lp(a) with CVD in FH were included. Studies written in a language other than English and for a non-adult population were excluded. The title and abstract of all studies identified through the search were screened. In addition, the reference lists of the retrieved articles were searched for further identification of relevant studies.

Statistical analysis

The studies reporting the CVD risk by Lp(a), as odds ratio (OR) and risk/hazard ratio (HR) with 95% confidence interval (CI), were finally collected. When multivariate estimates were reported, the maximally adjusted estimates were extracted. The OR in cross-sectional studies and the RR and HR in cohort studies were used to assess the risk of CVD by high Lp(a) levels compared to low Lp(a) levels. Random-effects meta-analyses for CVD outcomes were performed in the Review Manager software program (RevMan ver. 5.3) using the generic inverse variance method. The results were expressed as the OR and HR with 95% CIs, and heterogeneity was assessed using I 2 statistics. In addition, when the OR and HR were considered approximately equivalent as relative risks, an integrated meta-analysis was performed.

Results

Figure 1 shows the flow for selecting articles that reported the relationship of Lp(a) with CVD outcomes. Of the 43 initially identified articles, 25 that did not focus on this relationship were excluded. After reviewing the full text and the reference lists of all retrieved articles, eight articles [1522] met the criteria. The 8 studies (8,378 participants and 1,458 CVD outcomes) included 2 cross-sectional studies and 6 cohort studies.

Figure 1

Flow diagram of study selection

/f/fulltexts/AMSAD/41236/AMS-AD-5-41236-g001_min.jpg

Table I shows a summary of the association of Lp(a) with CVD in the two cross-sectional studies. As shown in Figure 2, the two studies found high Lp(a) levels to be positively associated with CVD compared to low Lp(a) levels (OR = 2.57; 95% CI: 1.16–5.73; I 2 = 49%). A summary of the prediction of Lp(a) on CVD is shown in Table II in six cohort studies. High Lp(a) levels predicted CVD compared to low Lp(a) levels with HR (1.91; 95% CI: 1.50–2.43; I 2 = 59%; Figure 3). In addition, the integrated relative risk of all studies was 1.97 (95% CI: 1.57–2.46; I 2 = 53%).

Table I

The association of Lp(a) with CVD by odds ratio in two cross-sectional studies

Authors [ref. no.]YearSubjects (n) CVD/non-CVDAge [years] CVD/non-CVDConfoundersCut-off level of Lp(a)OR (95% CI)
Chan [15]201564/32657/4350 mg/dl1.90 (1.09–3.31)
Sun [16]201861/8749/45Age, sex, smoking, hypertension, diabetes mellitus, body mass index, high-density lipoprotein cholesterol, statin, family history of CVD60 mg/dl4.46 (1.55–12.83)

[i] CI – confidence interval, CVD – cardiovascular disease, Lp(a) – lipoprotein(a), n – number, OR – odds ratio, ref. no. – reference number.

Table II

The prediction of Lp(a) for CVD by risk ratio in three cohort studies

Authors [ref. no.]YearSubjects (number) CVD/non-CVDAge [years] CVD/non-CVDConfoundersCut-off level of Lp(a)HR (95% CI)
Jansen [17]2004782/161850.4/42.0Sex, smoking, hypertension, diabetes mellitus, body mass index, high-density lipoprotein cholesterol, triglyceride, homocysteine30 mg/dl1.50 (1.20–1.79)
Holmes [18]200561/32753.0Sex, smoking, hypertension, total cholesterol/high-density lipoprotein cholesterol, low-density lipoprotein cholesterol56 mg/dl2.59 (1.53–4.39)
Allard [19]201474/22167.7/58.0Sex, smoking, diabetes mellitus, body mass index, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, family history of premature CVD60 mg/dl1.8 (1.1–2.9)
Alonso [20]2014247/171344.450 mg/dl2.07 (1.64–2.61)
Pérez De Isla [21]2015122/18544.5Age, sex, smoking, hypertension, diabetes mellitus, waist circumference, body mass index, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, history of CVD, statin50 mg/dl1.52 (1.05–2.21)
Cao [22]201935/35850.3/48.5triglyceride, total cholesterol52.0 mg/dl6.96 (2.24–9.32)

[i] CI – confidence interval, CVD – cardiovascular disease, HR – hazard ratio, Lp(a) – lipoprotein(a), ref. no. – reference number.

Figure 2

Forest plot based on a meta-analysis of the odds ratio in the association of lipoprotein(a) with cardiovascular disease in cross-sectional studies

/f/fulltexts/AMSAD/41236/AMS-AD-5-41236-g002_min.jpg
Figure 3

Forest plot based on a meta-analysis of the risk/hazard ratio in the association of lipoprotein(a) with cardiovascular disease in cohort studies

/f/fulltexts/AMSAD/41236/AMS-AD-5-41236-g003_min.jpg

Discussion

The current meta-analysis reviewed the relationship of Lp(a) with CVD outcomes in FH subjects. The findings from the meta-analysis showed that a high Lp(a) level remained a risk factor for CVD among FH subjects.

This meta-analysis revealed the risk of CVD as an OR of 2.57 and HR of 1.91, as well as an integrated relative risk of 1.97. In an earlier meta-analysis of the relationship of Lp(a) with CVD in a general population, an RR of 1.57 for CVD was demonstrated when the group with the high Lp(a) level was compared to that with the low level [5]. In a cohort study of hypercholesterolemic subjects with LDL-C of ≥ 3.1 mmol/l (121 mg/dl), the HR of 1.64 for CVD was demonstrated when the group with a high Lp(a) level (≥ 44 mg/dl) was compared to that with a low level [11]. The risk for CVD with Lp(a) among FH subjects, as observed in the current meta-analysis, seemed to be similar to or slightly high relative to the risks described for these data [5, 11].

The threshold of Lp(a) causing CVD may be debatable [3, 11]. While there is an opinion that a linear relationship without a threshold exists between the Lp(a) levels and CVD outcomes among general populations [23], an Lp(a) of 30–50 mg/dl is often used as the cut-off level for CVD [24, 25]. The European guideline states that the desired Lp(a) level for the prevention of CVD is < 50 mg/dl for general populations and CVD subjects [26]. As most studies included in the current meta-analysis used cut-off levels of 50 or 60 mg/dl (as shown in Tables I and II), this might induce a somewhat high risk in FH subjects relative to general populations and generic/common hypercholesterolemic subjects [5, 11].

While LDL-C is a main target for the management in FH subjects, the current study findings suggest the need for attention to Lp(a) levels during management. Statins (HMG-CoA reductase inhibitors) are representative lipid-lowering drugs in hypercholesterolemic subjects, including FH subjects [2729]. Therapies involving statins can increase or decrease Lp(a) levels [2729]. Whether or not the statin effects influence the relative risk for CVD with Lp(a) in FH subjects is unclear. Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been used to treat high LDL-C levels in conditions such as FH, and these inhibitors reduce not only LDL-C but also Lp(a) levels [30]. The effect of reduction of Lp(a) by intervention with PCSK9 inhibitors on the relationship between Lp(a) and CVD should be explored in the future.

Several limitations associated with the current study warrant mention. First, there were not many studies included for the purpose of this topic. Second, confounding factors (e.g. obesity, hypertension) in the adjusted analysis were not fully unified across the studies.

In conclusion, the current meta-analysis revealed that FH subjects with high Lp(a) levels could have a high risk of CVD, and in addition to LDL-C, attention should be paid to Lp(a) levels in FH subjects.

Conflict of interest

The authors declare no conflict of interest.

References

1 

Schmidt K, Noureen A, Kronenberg F, Utermann G , authors. Structure, function, and genetics of lipoprotein (a. J Lipid Res. 2016. 57:p. 1339–59

2 

Van Der Valk FM, Bekkering S, Kroon J, et al. , authors. Oxidized phospholipids on Lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016. 134:p. 611–24

3 

Kotani K, Serban MC, Penson P, Lippi G, Banach M , authors. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – some answers and still many questions. Crit Rev Clin Lab Sci. 2016. 53:p. 370–8

4 

Nave AH, Lange KS, Leonards CO, et al. , authors. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015. 242:p. 496–503

5 

Genser B, Dias KC, Siekmeier R, Stojakovic T, Grammer T, Maerz W , authors. Lipoprotein (a) and risk of cardiovascular disease – a systematic review and meta analysis of prospective studies. Clin Lab. 2011. 57:p. 143–56

6 

Feng Z, Li HL, Bei WJ, et al. , authors. Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention. Clin Cardiol. 2017. 40:p. 674–8

7 

Burgess S, Ference BA, Staley JR, et al. , authors. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis. JAMA Cardiol. 2018. 3:p. 619–27

8 

Soutar AK, Naoumova RP , authors. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007. 4:p. 214–25

9 

Nordestgaard BG, Chapman MJ, Humphries SE, et al. , authors. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013. 34:p. 3478–90

10 

Mabuchi H, Koizumi J, Shimizu M, Takeda R , authors. Development of coronary heart disease in familial hypercholesterolemia. Circulation. 1989. 79:p. 225–332

11 

Danik JS, Rifai N, Buring JE, Ridker PM , authors. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. J Am Med Assoc. 2006. 296:p. 1363–70

12 

Afshar M, Pilote L, Dufresne L, Engert JC, Thanassoulis G , authors. Lipoprotein(a) interactions with low-density lipoprotein cholesterol and other cardiovascular risk factors in premature acute coronary syndrome (ACS. J Am Heart Assoc. 2016. 5:p. e003012

13 

Ellis KL, Pang J, Chieng D, et al. , authors. Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: between Scylla and Charybdis. Clin Cardiol. 2018. 41:p. 378–84

14 

Ellis KL, Pérez de Isla L, Alonso R, Fuentes F, Watts GF, Mata P , authors. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia. J Am Coll Cardiol. 2019. 73:p. 1029–39

15 

Chan DC, Pang J, Hooper AJ, et al. , authors. Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. Int J Cardiol. 2015. 201:p. 633–8

16 

Sun D, Zhou BY, Zhao X, et al. , authors. Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia. J Clin Lab Anal. 2018. 32:p. e22442

17 

Jansen ACM, Van Aalst-Cohen ES, Tanck MW, et al. , authors. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004. 256:p. 482–90

18 

Holmes DT, Schick BA, Humphries KH, Frohlich J , authors. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem. 2005. 51:p. 2067–73

19 

Allard MD, Saeedi R, Yousefi M, Frohlich J , authors. Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort. Lipids Health Dis. 2014. 13:p. 65

20 

Alonso R, Andres E, Mata N, et al. , authors. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014. 63:p. 1982–9

21 

Pérez De Isla L, Alonso R, Mata N, et al. , authors. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish familial hypercholesterolemia cohort study). Circulation. 2017. 135:p. 2133–44

22 

Cao YX, Jin JL, Guo YL, et al. , authors. Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia. Atherosclerosis. 2019. 291:p. 27–33

23 

Tipping RW, Ford CE, Simpson LM, et al. , authors. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. J Am Med Assoc. 2009. 302:p. 412–23

24 

Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG , authors. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen city heart study. Circulation. 2008. 117:p. 176–84

25 

Nago N, Kayaba K, Hiraoka J, et al. , authors. Lipoprotein(a) levels in the japanese population: Influence of age and sex, and relation to atherosclerotic risk factors: the Jichi Medical School cohort study. Am J Epidemiol. 1995. 141:p. 815–21

26 

Nordestgaard BG, Chapman MJ, Ray K, et al. , authors. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010. 31:p. 2844–53

27 

Yeang C, Hung MY, Byun YS, et al. , authors. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a. J Clin Lipidol. 2016. 10:p. 594–603

28 

Takagi H, Umemoto T , authors. Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials. Int J Cardiol. 2012. 154:p. 183–6

29 

Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL , authors. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020. 41:p. 2275–84

30 

Kotani K , author. Lipoprotein(a) in the advent of a PCSK9 world. Ann Clin Biochem. 2020. 57:p. 102

Copyright: © 2020 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe